The short version of melanocortin receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-26 and is reviewed periodically as new material appears.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
In one study, two groups of treatment replicates from mammalian samples (different organisms with similar treatment histories, but not technical replicates) show dozens of low CV protein biomarkers, suggesting that IPEx is a viable technology for studying protein expression.
==== Quitting writing and The Chain ==== McKinty quit writing in 2017 after being evicted from his rented house, citing a lack of income from his novels, and instead took work as an Uber driver and a bartender. Upon hearing of his situation, fellow crime author Don Winslow passed some of his books to his agent, the screenwriter and producer Shane Salerno. In a late-night phone call, Salerno persuaded McKinty to write what would become The Chain. Salerno loaned the author ("advance on the advance") $10,000 to help him survive financially during the process. The stand-alone thriller was inspired by the chain letters of his youth and contemporary reports of hostage exchanges. McKinty returned to writing after the book landed him a six-figure English-language book deal, and was optioned for a film adaptation by Paramount Pictures. In an interview on CBS McKinty talked about never giving up and took the interviewer, Jeff Glor, to Plum Island, Massachusetts, where The Chain is set. The Chain was published in 37 countries.
Conflict Analysis Resources Center. Archived from the original on July 4, 2007. Colombian-based private research center that studies the conflict (In Spanish and English) "Colombian Army website". Archived from the original on September 27, 2007. Retrieved February 24, 2006. (In Spanish and English) "Colombian President's Office". Archived from the original on November 18, 2008. Retrieved February 24, 2006. (In Spanish and English) "Background Note: Colombia". U.S. Department of State. Retrieved February 11, 2006. "Different Views of Colombian Territory". Retrieved February 24, 2006. Maps of the conflict. "AUC Official Website". Retrieved February 24, 2006. (in Spanish) "FARC website". Archived from the original on July 5, 2008. Retrieved July 12, 2008. (in Spanish and English) – No longer available online (censored by U.S. government) "Civil War? The Language of Conflict in Colombia" (PDF). Ideas for Peace Foundation. Archived from the original (PDF) on September 10, 2009. Retrieved February 24, 2006. (PDF) Is the Colombia conflict a civil war? "The Peace Village San José Must Live". SOS San Jose. Archived from the original on January 12, 2006. Retrieved February 24, 2006. (in German and English) "Washington Office on Latin America". Retrieved February 24, 2006. "Who Shot My Brother?". National Film Board of Canada. Archived from the original on May 24, 2007. Retrieved May 27, 2018. "Why the End of the Cold War Doesn't Matter: the US War of Terror in Colombia". Bristol University Politics Department. Archived from the original on October 1, 2005.
Sources: en.wikipedia.org
Another independent approach is to use oligoadenylated anti-telomerase antisense oligonucleotides and ribozymes to target telomerase RNA, leading to the dissociation of the RNA and to apoptosis (Figure 5). The fast induction of apoptosis through antisense binding may be a good alternative to the slower telomere shortening.
== Description == N. christyi is a medium to moderately long, somewhat compressed, moderately slender-bodied, but heavily built snake, with a medium length tapering tail. The head is short, with an indistinct canthus, and is distinct from the neck. The neck is capable of being spread into a hood. The eyes are relatively small in size with round pupils. The dorsal scales are smooth and shiny. The average total length (including tail) of an adult specimen is around 1.1 metres (3.6 ft), but it may grow to upwards of 2.3 metres (7.5 ft) The rostral is once and a half as broad as deep, and is just visible from above. The internasals are as long as the prefrontals, and are extensively in contact with the preocular. The frontal is small, not longer than broad, broadest behind, forming very open angles in front and behind, not quite as long as its distance from the rostral, half as long as the parietals. The supraocular is much narrower than the frontal. The posterior nasal is in contact with the single preocular. There are two or three postoculars. The temporals are 2+2 or 2+3. There are seven upper labials, the third and fourth entering the eye, the fourth and fifth in contact with the lower postocular. There are four lower labials in contact with the anterior chin shields. The posterior chin shields are narrower and a little shorter than the anterior chin shields and separated by one scale. The dorsal scales are in 19 rows on the neck, and in 17 rows at midbody. The ventrals number 221. The anal is entire. The subcaudals number 70. Colouration is blackish brown above.
An UP element upstream of the rrn P1 promoter can bind a subunit of RNA polymerase, thus promoting transcription of rRNA. Transcription factors such as FIS bind upstream of the promoter and interact with RNA polymerase which facilitates transcription. Anti-termination factors bind downstream of the rrn P2 promoter, preventing premature transcription termination. Due to the stringent response, when the availability of amino acids is low, ppGpp (a negative effector) can inhibit transcription from both the P1 and P2 promoters.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.